The Finnish cancer registry study suggested that pT1a, b N0M0 patients had an excellent prognosis with distant disease‐free survival reached up to 100%.11 Whereas, data from a French study revealed HER2 positivity had an independent correlation with cancer recurrence and mortality in anti‐HER2 treatment naïve patients.12 These contradictory results made it difficult to balance the survival benefit and potential treatment related toxic effects in managing pT1a‐1c HER2+ cancer. Here, ERBB2 is linked to cancer.